You just read:

NewVac Reports Primary Endpoint Met in Phase II Clinical Trial of Quisinostat in Combination with Paclitaxel and Carboplatin in Platinum-Resistant Ovarian Cancer

News provided by

NewVac LLC

Jan 03, 2017, 10:43 ET